The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy and ViiV’s Dovato,…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, or an oral diuretic. The addition of a second- or third-…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. Individuals…
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Disorders such as anxiety, substance use disorder, and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists and primary care…
Copy/Paste the core content from the latest edited report brochure. DELETE the “Market Outlook” header from the top. Venous thromboembolism (VTE) is the obstruction of a vein caused by a…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Since 2012,…
Myasthenia gravis (MG) is a rare neuromuscular disorder commonly caused by autoantibodies targeting acetylcholine (ACh) receptors and therefore affecting neuromuscular synaptic transmission at the…
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF/MEK inhibitor…
Immune checkpoint inhibitors continue to dominate the treatment of non-small cell lung cancer (NSCLC), and biomarker-based approaches are increasingly segmenting the space and providing new…